首页> 外文期刊>Scientific reports. >Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine
【24h】

Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine

机译:免疫信息学方法探讨幽门螺杆菌蛋白质组(毒力因子)设计B和T细胞多表位亚基疫苗

获取原文
           

摘要

Helicobacter Pylori is a known causal agent of gastric malignancies and peptic ulcers. The extremophile nature of this bacterium is protecting it from designing a potent drug against it. Therefore, the use of computational approaches to design antigenic, stable and safe vaccine against this pathogen could help to control the infections associated with it. Therefore, in this study, we used multiple immunoinformatics approaches along with other computational approaches to design a multi-epitopes subunit vaccine against H. Pylori. A total of 7 CTL and 12 HTL antigenic epitopes based on c-terminal cleavage and MHC binding scores were predicted from the four selected proteins (CagA, OipA, GroEL and cagA). The predicted epitopes were joined by AYY and GPGPG linkers. Β-defensins adjuvant was added to the N-terminus of the vaccine. For validation, immunogenicity, allergenicity and physiochemical analysis were conducted. The designed vaccine is likely antigenic in nature and produced robust and substantial interactions with Toll-like receptors (TLR-2, 4, 5, and 9). The vaccine developed was also subjected to an in silico cloning and immune response prediction model, which verified its efficiency of expression and the immune system provoking response. These analyses indicate that the suggested vaccine may produce particular immune responses against H. pylori, but laboratory validation is needed to verify the safety and immunogenicity status of the suggested vaccine design.
机译:幽门螺杆菌是一种已知的胃恶性肿瘤和消化溃疡的原因。这种细菌的鼻尖性质正在保护它以设计有效的药物对抗它。因此,使用计算方法来设计抗原性,稳定和安全的疫苗对该病原体有助于控制与其相关的感染。因此,在本研究中,我们使用多种免疫信息方法以及其他计算方法,以设计针对幽门螺杆菌的多表位亚基疫苗。从四种选定的蛋白质(CAGA,OIPA,GROEL和CAGA)预测了基于C末端切割和MHC结合分数的7个CTL和12个HTL抗原性表位。预测表位通过Ayy和GPGPG接头连接。将β-脱蜡素佐剂加入疫苗的N-末端。对于验证,进行免疫原性,过敏性和生理化学分析。设计的疫苗本质上是抗原性,并产生与Toll样受体(TLR-2,4,5和9)产生的稳健和实质相互作用。疫苗也经过硅克隆和免疫响应预测模型的疫苗,其验证了其表达效率和免疫系统引发反应。这些分析表明,建议的疫苗可以产生针对幽门螺杆菌的特定免疫应答,但需要实验室验证来验证建议疫苗设计的安全性和免疫原性状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号